These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21871940)

  • 21. Polio programme: let us declare victory and move on.
    Vashisht N; Puliyel J
    Indian J Med Ethics; 2012; 9(2):114-7. PubMed ID: 22591873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010.
    Goldman GS; Miller NZ
    Hum Exp Toxicol; 2012 Oct; 31(10):1012-21. PubMed ID: 22531966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts.
    LaRussa P; Steinberg S; Meurice F; Gershon A
    J Infect Dis; 1997 Oct; 176(4):1072-5. PubMed ID: 9333170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease.
    Gherardi RK; Aouizerate J; Cadusseau J; Yara S; Authier FJ
    Morphologie; 2016 Jun; 100(329):85-94. PubMed ID: 26948677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis.
    Krauss SR; Barbateskovic M; Klingenberg SL; Djurisic S; Petersen SB; Kenfelt M; Kong Z; Jakobsen JC; Gluud C
    BMJ Open; 2022 Jun; 12(6):e058795. PubMed ID: 35738649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis.
    Khatami M
    Clin Transl Med; 2020 Dec; 10(8):e215. PubMed ID: 33377661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?
    Petersen SB; Gluud C
    BMJ Evid Based Med; 2021 Dec; 26(6):285-289. PubMed ID: 32763959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.
    Shardlow E; Mold M; Exley C
    Allergy Asthma Clin Immunol; 2018; 14():80. PubMed ID: 30455719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.
    Inbar R; Weiss R; Tomljenovic L; Arango MT; Deri Y; Shaw CA; Chapman J; Blank M; Shoenfeld Y
    Immunol Res; 2017 Feb; 65(1):136-149. PubMed ID: 27421722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zinc Improves Cognitive and Neuronal Dysfunction During Aluminium-Induced Neurodegeneration.
    Singla N; Dhawan DK
    Mol Neurobiol; 2017 Jan; 54(1):406-422. PubMed ID: 26742519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminum-induced entropy in biological systems: implications for neurological disease.
    Shaw CA; Seneff S; Kette SD; Tomljenovic L; Oller JW; Davidson RM
    J Toxicol; 2014; 2014():491316. PubMed ID: 25349607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy.
    Exley C
    Allergy Asthma Clin Immunol; 2014 Jan; 10(1):4. PubMed ID: 24444186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aluminium-based adjuvants should not be used as placebos in clinical trials.
    Exley C
    Vaccine; 2011 Nov; 29(50):9289. PubMed ID: 21871940
    [No Abstract]   [Full Text] [Related]  

  • 34. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes.
    Exley C
    Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301
    [No Abstract]   [Full Text] [Related]  

  • 35. The mechanism of adjuvanticity of aluminium-containing formulas.
    Fierens K; Kool M
    Curr Pharm Des; 2012; 18(16):2305-13. PubMed ID: 22390693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using bicistronic IL-4 reporter mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant.
    McDonald F; Mohrs M; Brewer J
    Vaccine; 2006 Jun; 24(26):5393-9. PubMed ID: 16630673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (How) do aluminium adjuvants work?
    Brewer JM
    Immunol Lett; 2006 Jan; 102(1):10-5. PubMed ID: 16188325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents.
    Theeten H; Van Damme P; Hoppenbrouwers K; Vandermeulen C; Leback E; Sokal EM; Wolter J; Schuerman L
    Vaccine; 2005 Feb; 23(12):1515-21. PubMed ID: 15670888
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.